An increase in Treg cells was observed at the doses tested without any significant increases in Teff cells.26 Part B, which included patients with ACS (non-ST elevation myocardial infarction (NSTEMI) and unstable angina (UA)), was carried out on completion of part A. Two doses (1.5×106 and 2.5×106 IU) were used in part B (IL-2: placebo=6:2). This evidence concerns the gene IL2 and angina pectoris.